Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy.

Abstract

Despite the many advantages of small interfering RNA (siRNA) inhalation therapy and a growing prevalence of respiratory pathologies, its clinical translation is severely hampered by inefficient intracellular delivery. To this end, we previously developed hybrid nanoparticles consisting of an siRNA-loaded nanosized hydrogel core (nanogel) coated with Curosurf®, a clinically used pulmonary surfactant (PS). Interestingly, the PS shell was shown to markedly improve particle stability as well as intracellular siRNA delivery in vitro and in vivo. The major aim of this work was to identify the key molecular components of PS responsible for the enhanced siRNA delivery and evaluate how the complexity of the PS coat could be reduced. We identified surfactant protein B (SP-B) as a potent siRNA delivery enhancer when reconstituted in proteolipid coated hydrogel nanocomposites. Improved cytosolic siRNA delivery was achieved by inserting SP-B into a simplified phospholipid mixture prior to nanogel coating. This effect was observed both in vitro (lung epithelial cell line) and in vivo (murine acute lung injury model), albeit that distinct phospholipids were required to achieve these results. Importantly, the developed nanocomposites have a low in vivo toxicity and are efficiently taken up by resident alveolar macrophages, a main target cell type for treatment of inflammatory pulmonary pathologies. Our results demonstrate the potential of the endogenous protein SP-B as an intracellular siRNA delivery enhancer, paving the way for future design of nanoformulations for siRNA inhalation therapy.

STATEMENT OF SIGNIFICANCE:

Despite the therapeutic potential of small interfering RNA (siRNA) and a growing prevalence of lung diseases for which innovative therapies are needed, a safe and effective siRNA inhalation therapy remains non-existing due to a lack of suitable formulations. We identified surfactant protein B (SP-B) as a potent enhancer of siRNA delivery by proteolipid coated nanogel formulations in vitro in a lung epithelial cell line. The developed nanocomposites have a low in vivo toxicity and show a high uptake by alveolar macrophages, a main target cell type for treatment of inflammatory pulmonary pathologies. Importantly, in vivo SP-B is also critical for the developed formulation to obtain a significant silencing of TNFα in a murine LPS-induced acute lung injury model.

• Authors: Pieterjan Merckx, Lynn De Backer, Lien Van Hoecke, Roberta Guagliardo, Mercedes Echaide, Pieter Baatsen, Bárbara Olmeda, Xavier Saelens, Jésus Pérez-Gil, Stefaan C De Smedt, Koen Raemdonck
• Journal: Acta biomaterialia (Acta Biomater) Vol. 78 Pg. 236-246 (09 15 2018) ISSN: 1878-7568 [Electronic] England
• PMID: 30118853 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Lipopolysaccharides
• Nanogels
• Phospholipids
• Proteolipids
• Pulmonary Surfactant-Associated Protein B
• RNA, Small Interfering
• Tumor Necrosis Factor-alpha
• polyethylene glycol polyethyleneimine nanogel
• Polyethylene Glycols
• Polyethyleneimine

Topics

• Acute Lung Injury (pathology, therapy)
• Animals
• Cell Line
• Disease Models, Animal
• Female
• Gene Silencing
• Gene Transfer Techniques
• Humans
• Lipopolysaccharides
• Mice, Inbred BALB C
• Nanogels
• Phospholipids (chemistry)
• Polyethylene Glycols (chemistry, toxicity)
• Polyethyleneimine (chemistry, toxicity)
• Proteolipids (chemistry, toxicity)
• Pulmonary Surfactant-Associated Protein B (chemistry)
• RNA, Small Interfering (administration & dosage)
• Respiratory Therapy
• Tumor Necrosis Factor-alpha (metabolism)